$11.5 Billion is the total value of Baker Brothers Advisors's 123 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 11.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $3,241,973,000 | -18.9% | 34,230,523 | +0.0% | 28.10% | -13.3% |
| SGEN | Seattle Genetics, Inc. | $2,446,317,000 | -1.7% | 45,725,556 | 0.0% | 21.20% | +5.1% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,022,957,000 | -14.8% | 8,553,864 | 0.0% | 8.87% | -8.9% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $819,845,000 | -15.7% | 27,228,338 | +5.5% | 7.11% | -9.9% |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $676,184,000 | +23.0% | 7,583,084 | +28.4% | 5.86% | +31.5% |
| GHDX | Buy | Genomic Health, Inc. | $471,314,000 | +6.6% | 13,781,102 | +0.0% | 4.08% | +13.9% |
| BGNE | Sell | BeiGene, Ltd.sponsored adr | $376,147,000 | -6.7% | 3,849,231 | -1.3% | 3.26% | -0.3% |
| DBVT | DBV Technologies S.A.sponsored adr | $135,535,000 | -42.0% | 5,509,560 | 0.0% | 1.18% | -38.0% | |
| AQXP | Aquinox Pharmaceuticals, Inc. | $128,586,000 | -17.1% | 10,934,154 | 0.0% | 1.12% | -11.4% | |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $104,910,000 | +23.2% | 2,618,818 | +11.5% | 0.91% | +31.5% |
| ABLX | New | Ablynx NVsponsored adr | $103,986,000 | – | 4,161,118 | +100.0% | 0.90% | – |
| SAGE | Buy | Sage Therapeutics, Inc. | $101,546,000 | +302.0% | 616,514 | +52.0% | 0.88% | +329.3% |
| AMRN | Amarin Corporation plcsponsored adr new | $90,905,000 | +14.6% | 22,669,509 | 0.0% | 0.79% | +22.6% | |
| AVXS | AveXis, Inc. | $85,769,000 | +14.4% | 775,000 | 0.0% | 0.74% | +22.2% | |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $77,949,000 | +106.3% | 1,004,624 | +62.9% | 0.68% | +120.9% |
| ARRY | Buy | Array BioPharma Inc. | $72,399,000 | +12.9% | 5,656,196 | +8.5% | 0.63% | +20.8% |
| ONCE | Spark Therapeutics, Inc. | $71,172,000 | -42.3% | 1,384,130 | 0.0% | 0.62% | -38.4% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $68,726,000 | -6.3% | 13,997,172 | 0.0% | 0.60% | +0.2% | |
| ERYP | New | Erytech Pharma S.A.sponsored adr | $68,043,000 | – | 3,090,069 | +100.0% | 0.59% | – |
| NVTA | Invitae Corporation | $66,178,000 | -3.1% | 7,288,300 | 0.0% | 0.57% | +3.6% | |
| ARGX | Buy | argenx SEsponsored adr | $60,725,000 | +2585.8% | 961,754 | +861.8% | 0.53% | +2822.2% |
| RYTM | New | Rhythm Pharmaceuticals, Inc. | $59,545,000 | – | 2,049,020 | +100.0% | 0.52% | – |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $56,514,000 | +2075.3% | 615,684 | +965.9% | 0.49% | +2233.3% |
| HRTX | Buy | Heron Therapeutics, Inc. | $55,398,000 | +23.0% | 3,060,641 | +9.8% | 0.48% | +31.5% |
| MRTX | Buy | Mirati Therapeutics, Inc. | $46,528,000 | +75.3% | 2,549,461 | +12.4% | 0.40% | +87.4% |
| EXEL | Sell | Exelixis, Inc. | $45,798,000 | -9.2% | 1,506,499 | -27.6% | 0.40% | -2.9% |
| BLCM | Bellicum Pharmaceuticals, Inc. | $42,322,000 | -27.2% | 5,032,313 | 0.0% | 0.37% | -22.1% | |
| Novavax, Inc.note 3.75% 2/1/2023 | $40,863,000 | +3.4% | 88,500,000 | 0.0% | 0.35% | +10.3% | ||
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $38,646,000 | +68.1% | 18,315,802 | +77.7% | 0.34% | +80.1% |
| RXDX | Buy | Ignyta, Inc. | $36,960,000 | +130.4% | 1,384,266 | +6.5% | 0.32% | +146.2% |
| BLUE | Sell | bluebird bio, Inc. | $35,620,000 | +7.4% | 200,000 | -17.2% | 0.31% | +14.9% |
| SGMO | Sangamo Therapeutics, Inc. | $34,659,000 | +9.3% | 2,113,376 | 0.0% | 0.30% | +16.7% | |
| CERS | Cerus Corporation | $32,939,000 | +23.8% | 9,745,209 | 0.0% | 0.29% | +32.4% | |
| HALO | Halozyme Therapeutics, Inc. | $32,040,000 | +16.6% | 1,581,424 | 0.0% | 0.28% | +24.7% | |
| ABEO | Buy | Abeona Therapeutics Inc. | $31,452,000 | +9.5% | 1,984,364 | +17.8% | 0.27% | +17.2% |
| Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $29,751,000 | -5.8% | 35,083,000 | 0.0% | 0.26% | +0.8% | ||
| GWPH | Buy | GW Pharmaceuticals plcads | $29,280,000 | +284.7% | 221,800 | +195.7% | 0.25% | +309.7% |
| CBAY | CymaBay Therapeutics, Inc. | $27,524,000 | +14.1% | 2,991,775 | 0.0% | 0.24% | +21.9% | |
| AIMT | Aimmune Therapeutics, Inc. | $25,487,000 | +52.6% | 673,908 | 0.0% | 0.22% | +63.7% | |
| GLPG | Galapagos NVsponsored adr | $24,368,000 | -7.9% | 259,894 | 0.0% | 0.21% | -1.4% | |
| CPRX | Buy | Catalyst Pharmaceuticals, Inc. | $22,882,000 | +78.0% | 5,852,153 | +14.7% | 0.20% | +90.4% |
| MRUS | Merus N.V. | $22,504,000 | -2.4% | 1,160,014 | 0.0% | 0.20% | +4.3% | |
| NTLA | Buy | Intellia Therapeutics, Inc. | $22,016,000 | -16.6% | 1,145,453 | +7.8% | 0.19% | -10.7% |
| INSM | Insmed Incorporated | $21,826,000 | -0.1% | 700,000 | 0.0% | 0.19% | +6.8% | |
| XNCR | Xencor, Inc. | $19,116,000 | -4.4% | 872,072 | 0.0% | 0.17% | +2.5% | |
| PGNX | Progenics Pharmaceuticals, Inc. | $18,747,000 | -19.2% | 3,150,808 | 0.0% | 0.16% | -13.8% | |
| ANAB | Buy | AnaptysBio, Inc. | $18,269,000 | +369.3% | 181,386 | +62.8% | 0.16% | +393.8% |
| AERI | Aerie Pharmaceuticals, Inc. | $17,887,000 | +22.9% | 299,356 | 0.0% | 0.16% | +31.4% | |
| IMGN | Sell | ImmunoGen, Inc. | $16,432,000 | -20.1% | 2,563,489 | -4.6% | 0.14% | -15.0% |
| MYOK | MyoKardia, Inc. | $14,957,000 | -1.7% | 355,264 | 0.0% | 0.13% | +5.7% | |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $14,928,000 | -1.7% | 15,000,000 | 0.0% | 0.13% | +4.9% | ||
| FOMX | Foamix Pharmaceuticals Ltd. | $14,825,000 | +8.3% | 2,466,702 | 0.0% | 0.13% | +15.3% | |
| ASMB | Buy | Assembly Biosciences, Inc. | $14,603,000 | +67.3% | 322,727 | +29.1% | 0.13% | +78.9% |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $13,218,000 | -3.1% | 12,228,000 | 0.0% | 0.12% | +3.6% | ||
| NKTR | New | Nektar Therapeutics | $10,268,000 | – | 171,934 | +100.0% | 0.09% | – |
| LGND | Ligand Pharmaceuticals Incorporated | $10,049,000 | +0.6% | 73,386 | 0.0% | 0.09% | +7.4% | |
| STML | Stemline Therapeutics, Inc. | $9,883,000 | +40.5% | 633,497 | 0.0% | 0.09% | +50.9% | |
| RIGL | Rigel Pharmaceuticals, Inc. | $9,773,000 | +52.8% | 2,518,882 | 0.0% | 0.08% | +63.5% | |
| GLYC | GlycoMimetics, Inc. | $9,458,000 | +20.0% | 563,312 | 0.0% | 0.08% | +28.1% | |
| QURE | New | uniQure N.V. | $9,453,000 | – | 482,557 | +100.0% | 0.08% | – |
| ITCI | Intra-Cellular Therapies, Inc. | $8,821,000 | -8.2% | 609,166 | 0.0% | 0.08% | -2.6% | |
| NLNK | NewLink Genetics Corporation | $8,169,000 | -20.3% | 1,007,273 | 0.0% | 0.07% | -14.5% | |
| ACHN | Buy | Achillion Pharmaceuticals, Inc. | $8,227,000 | -1.3% | 2,856,637 | +53.9% | 0.07% | +4.4% |
| ALKS | Alkermes plc | $8,223,000 | +7.6% | 150,251 | 0.0% | 0.07% | +14.5% | |
| Aegerion Pharmaceuticals, Inc.note 2.0% 8/15/2019 | $7,566,000 | -0.1% | 9,517,000 | 0.0% | 0.07% | +8.2% | ||
| AGIO | Agios Pharmaceuticals, Inc. | $7,356,000 | -14.3% | 128,666 | 0.0% | 0.06% | -8.6% | |
| CFRX | ContraFect Corporation | $7,225,000 | -9.0% | 7,153,076 | 0.0% | 0.06% | -1.6% | |
| MGNX | MacroGenics, Inc. | $6,910,000 | +2.8% | 363,676 | 0.0% | 0.06% | +9.1% | |
| XLRN | Acceleron Pharma Inc. | $6,956,000 | +13.7% | 163,900 | 0.0% | 0.06% | +20.0% | |
| VNDA | Vanda Pharmaceuticals Inc. | $6,443,000 | -15.1% | 423,884 | 0.0% | 0.06% | -9.7% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $6,156,000 | +9.8% | 1,137,872 | 0.0% | 0.05% | +17.8% | |
| TTPH | Tetraphase Pharmaceuticals, Inc. | $5,891,000 | -7.9% | 935,000 | 0.0% | 0.05% | -1.9% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $5,850,000 | +60.1% | 172,630 | 0.0% | 0.05% | +70.0% | |
| Nabriva Therapeutics plc | $5,611,000 | -27.0% | 938,235 | 0.0% | 0.05% | -21.0% | ||
| SYRS | Syros Pharmaceuticals, Inc. | $5,593,000 | -33.9% | 574,835 | 0.0% | 0.05% | -30.4% | |
| ALBO | Albireo Pharma, Inc. | $5,120,000 | +22.2% | 200,000 | 0.0% | 0.04% | +29.4% | |
| LJPC | La Jolla Pharmaceutical Company | $4,977,000 | -7.5% | 154,675 | 0.0% | 0.04% | -2.3% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $5,015,000 | -20.2% | 373,144 | 0.0% | 0.04% | -15.7% | |
| GNMX | Sell | Aevi Genomic Medicine, Inc. | $4,866,000 | -15.0% | 4,055,142 | -10.8% | 0.04% | -8.7% |
| CMTA | Clementia Pharmaceuticals Inc. | $4,745,000 | +12.4% | 250,000 | 0.0% | 0.04% | +20.6% | |
| CRBP | New | Corbus Pharmaceuticals Holdings, Inc. | $4,691,000 | – | 660,714 | +100.0% | 0.04% | – |
| ECYT | New | Endocyte, Inc. | $4,654,000 | – | 1,087,323 | +100.0% | 0.04% | – |
| AAAP | Sell | Advanced Accelerator Applications S.A.sponsored ads | $4,499,000 | -97.0% | 55,125 | -97.5% | 0.04% | -96.8% |
| ACOR | Sell | Acorda Therapeutics, Inc. | $4,418,000 | -64.0% | 205,966 | -60.4% | 0.04% | -62.0% |
| IFRX | New | InflaRx N.V. | $4,190,000 | – | 200,000 | +100.0% | 0.04% | – |
| INOTEK Technologies Corp.note 5.75% 8/1/2021 | $4,009,000 | +2.7% | 5,000,000 | 0.0% | 0.04% | +9.4% | ||
| OVID | Ovid Therapeutics Inc. | $3,290,000 | +15.2% | 333,333 | 0.0% | 0.03% | +26.1% | |
| VSAR | Sell | Versartis, Inc. | $3,138,000 | -10.9% | 1,426,310 | -0.8% | 0.03% | -6.9% |
| AKTX | Buy | Akari Therapeutics Plcsponsored adr | $3,018,000 | -1.1% | 696,901 | +40.2% | 0.03% | +4.0% |
| Sell | Trillium Therapeutics Inc. | $2,968,000 | +39.3% | 409,323 | -1.1% | 0.03% | +52.9% | |
| EPZM | Epizyme, Inc. | $2,918,000 | -34.1% | 232,481 | 0.0% | 0.02% | -30.6% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $2,737,000 | +90.2% | 741,665 | 0.0% | 0.02% | +100.0% | |
| SELB | Sell | Selecta Biosciences, Inc. | $2,783,000 | -47.4% | 283,716 | -2.1% | 0.02% | -44.2% |
| Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $2,576,000 | 0.0% | 3,423,000 | 0.0% | 0.02% | +4.8% | ||
| NVAX | Novavax, Inc. | $2,480,000 | +8.8% | 2,000,000 | 0.0% | 0.02% | +16.7% | |
| TNXP | Tonix Pharmaceuticals Holdings Corp. | $2,413,000 | -24.4% | 699,500 | 0.0% | 0.02% | -19.2% | |
| KPTI | Karyopharm Therapeutics Inc. | $2,083,000 | -12.6% | 216,990 | 0.0% | 0.02% | -5.3% | |
| NTRA | Natera, Inc. | $2,056,000 | -30.3% | 228,676 | 0.0% | 0.02% | -25.0% | |
| KRYS | Krystal Biotech, Inc. | $2,104,000 | +5.5% | 200,000 | 0.0% | 0.02% | +12.5% | |
| CLLS | Cellectis S.A.sponsored ads | $1,458,000 | +2.5% | 50,000 | 0.0% | 0.01% | +8.3% | |
| RARX | Ra Pharmaceuticals, Inc. | $1,513,000 | -41.8% | 177,952 | 0.0% | 0.01% | -38.1% | |
| TRVN | Trevena, Inc. | $1,520,000 | -37.3% | 950,000 | 0.0% | 0.01% | -35.0% | |
| DVAX | Dynavax Technologies Corporation | $1,403,000 | -13.0% | 75,000 | 0.0% | 0.01% | -7.7% | |
| AKAOQ | Sell | Achaogen, Inc. | $1,315,000 | -97.9% | 122,482 | -96.8% | 0.01% | -97.8% |
| JNCE | Jounce Therapeutics, Inc. | $1,275,000 | -18.2% | 100,000 | 0.0% | 0.01% | -15.4% | |
| INFI | Infinity Pharmaceuticals, Inc. | $1,178,000 | +52.6% | 580,400 | 0.0% | 0.01% | +66.7% | |
| MDWD | MediWound Ltd. | $1,006,000 | -16.8% | 226,000 | 0.0% | 0.01% | -10.0% | |
| ABUS | Arbutus Biopharma Corporation | $912,000 | -18.6% | 180,582 | 0.0% | 0.01% | -11.1% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $922,000 | -5.9% | 2,800,000 | 0.0% | 0.01% | 0.0% | |
| MTEM | Molecular Templates, Inc. | $726,000 | +43.8% | 72,412 | 0.0% | 0.01% | +50.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $668,000 | -18.4% | 100,000 | 0.0% | 0.01% | -14.3% | |
| FLGT | Fulgent Genetics, Inc. | $548,000 | -8.5% | 125,000 | 0.0% | 0.01% | 0.0% | |
| PRTO | Proteon Therapeutics, Inc. | $567,000 | -5.0% | 298,591 | 0.0% | 0.01% | 0.0% | |
| BDSI | BioDelivery Sciences International, Inc. | $620,000 | 0.0% | 210,021 | 0.0% | 0.01% | 0.0% | |
| IMDZ | Immune Design Corp. | $581,000 | -62.3% | 148,937 | 0.0% | 0.01% | -58.3% | |
| AFMD | Affimed N.V. | $520,000 | -42.2% | 400,000 | 0.0% | 0.01% | -28.6% | |
| TTOO | T2 Biosystems, Inc. | $412,000 | -1.9% | 100,000 | 0.0% | 0.00% | +33.3% | |
| FPRX | Five Prime Therapeutics, Inc. | $422,000 | -46.4% | 19,247 | 0.0% | 0.00% | -33.3% | |
| CCXI | ChemoCentryx, Inc. | $292,000 | -19.8% | 49,064 | 0.0% | 0.00% | 0.0% | |
| NVIV | Sell | InVivo Therapeutics Holdings Corp. | $255,000 | -56.0% | 331,393 | -17.2% | 0.00% | -60.0% |
| TENX | Tenax Therapeutics, Inc. | $171,000 | +35.7% | 348,374 | 0.0% | 0.00% | 0.0% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $92,000 | -6.1% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $2,000 | -50.0% | 20,084 | 0.0% | 0.00% | – | |
| BPMX | Exit | BioPharmX Corporation | $0 | – | -598,758 | -100.0% | -0.00% | – |
| VYGR | Exit | Voyager Therapeutics, Inc. | $0 | – | -237,014 | -100.0% | -0.04% | – |
| Exit | Array BioPharma Inc.note 3.0% 6/1/2020 | $0 | – | -3,000,000 | -100.0% | -0.04% | – | |
| DMTX | Exit | Dimension Therapeutics, Inc. | $0 | – | -1,251,881 | -100.0% | -0.06% | – |
| LOXO | Exit | Loxo Oncology, Inc. | $0 | – | -96,062 | -100.0% | -0.07% | – |
| Exit | NeuroDerm Ltd. | $0 | – | -571,667 | -100.0% | -0.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.